Metabotropic Glutamate Receptors Type 3 and 5 Feature the "NeuroTransmitter-type" of Glioblastoma: A Bioinformatic Approach.

IF 4.8 2区医学 Q1 NEUROSCIENCES

Current Neuropharmacology Pub Date : 2024-01-01 DOI:10.2174/1570159X22666240320112926

Matteo Caridi, Marika Alborghetti, Valeria Pellicelli, Rosamaria Orlando, Francesco Ernesto Pontieri, Giuseppe Battaglia, Antonietta Arcella

{"title":"Metabotropic Glutamate Receptors Type 3 and 5 Feature the \"NeuroTransmitter-type\" of Glioblastoma: A Bioinformatic Approach.","authors":"Matteo Caridi, Marika Alborghetti, Valeria Pellicelli, Rosamaria Orlando, Francesco Ernesto Pontieri, Giuseppe Battaglia, Antonietta Arcella","doi":"10.2174/1570159X22666240320112926","DOIUrl":null,"url":null,"abstract":"Background: Glioblastoma (GBM) represents an aggressive and common tumor of the central nervous system. The prognosis of GBM is poor, and despite a refined genetic and molecular characterization, pharmacological treatment is largely suboptimal.Objective: Contribute to defining a therapeutic line in GBM targeting the mGlu3 receptor in line with the principles of precision medicine.Methods: Here, we performed a computational analysis focused on the expression of type 3 and 5 metabotropic glutamate receptor subtypes (mGlu3 and mGlu5, respectively) in high- and low-grade gliomas.Results: The analysis allowed the identification of a particular high-grade glioma type, characterized by a high expression level of both receptor subtypes and by other markers of excitatory and inhibitory neurotransmission. This so-called neurotransmitter-GBM (NT-GBM) also shows a distinct immunological, metabolic, and vascularization gene signature.Conclusion: Our findings might lay the groundwork for a targeted therapy to be specifically applied to this putative novel type of GBM.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":"1923-1939"},"PeriodicalIF":4.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284726/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1570159X22666240320112926","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Glioblastoma (GBM) represents an aggressive and common tumor of the central nervous system. The prognosis of GBM is poor, and despite a refined genetic and molecular characterization, pharmacological treatment is largely suboptimal.

Objective: Contribute to defining a therapeutic line in GBM targeting the mGlu3 receptor in line with the principles of precision medicine.

Methods: Here, we performed a computational analysis focused on the expression of type 3 and 5 metabotropic glutamate receptor subtypes (mGlu3 and mGlu5, respectively) in high- and low-grade gliomas.

Results: The analysis allowed the identification of a particular high-grade glioma type, characterized by a high expression level of both receptor subtypes and by other markers of excitatory and inhibitory neurotransmission. This so-called neurotransmitter-GBM (NT-GBM) also shows a distinct immunological, metabolic, and vascularization gene signature.

Conclusion: Our findings might lay the groundwork for a targeted therapy to be specifically applied to this putative novel type of GBM.

查看原文本刊更多论文

神经传导型 "胶质母细胞瘤的3型和5型代谢谷氨酸受体特征：一种生物信息学方法。

背景：胶质母细胞瘤（GBM胶质母细胞瘤（GBM）是一种侵袭性中枢神经系统常见肿瘤。GBM 的预后很差，尽管对其基因和分子特征进行了细化，但药物治疗在很大程度上并不理想：方法：在此，我们对高分化和低分化胶质瘤中 3 型和 5 型代谢谷氨酸受体亚型（分别为 mGlu3 和 mGlu5）的表达进行了计算分析：结果：通过分析发现了一种特殊的高级别胶质瘤类型，其特点是两种受体亚型以及其他兴奋性和抑制性神经递质标记物的高表达水平。这种所谓的神经递质-GBM（NT-GBM）还显示出独特的免疫、代谢和血管化基因特征：我们的研究结果可能为专门针对这种假定的新型 GBM 的靶向疗法奠定了基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Neuropharmacology 医学-神经科学

CiteScore

8.70

自引率

1.90%

发文量

369

审稿时长

>12 weeks

期刊介绍： Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience. The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.